[{"id":"d4485f54-359c-4ee3-8554-f4f3c66c58bb","acronym":"TNG462-C101","url":"https://clinicaltrials.gov/study/NCT05732831","created_at":"2023-02-17T15:00:50.938Z","updated_at":"2025-02-25T14:41:52.620Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","source_id_and_acronym":"NCT05732831 - TNG462-C101","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vopimetostat (TNG462)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 05/26/2023","start_date":" 05/26/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-14"}]